Fagron publishes its annual report 2024
06 March 2025 - 5:00PM
UK Regulatory
Fagron publishes its annual report 2024
Regulated information – inside information
Nazareth (Belgium)/Rotterdam (The Netherlands), 6 March 2025 – 7AM
CET
Fagron publishes its annual report 2024
Fagron, the leading global player in
pharmaceutical compounding, today publishes its annual report 2024.
Discussion of the annual report and the approval of the financial
statements will be put on the agenda of the annual general meeting
of shareholders scheduled for 12 May 2025.
The annual report is available in the official
Dutch version and in English translation on Fagron’s website.
Further information
Ignacio Artola
Global Investor Relations Leader
Tel. +34 670 385 795
ignacio.artola@fagron.com
About Fagron
Fagron is a leading global company active in pharmaceutical
compounding, focusing on delivering personalized medicine to
hospitals, pharmacies, clinics, and patients in more than 30
countries around the world.
The Belgian company Fagron NV has its registered
office in Nazareth and is listed on Euronext Brussels and Euronext
Amsterdam under the ticker symbol ‘FAGR’. Fagron’s operational
activities are managed by the Dutch company Fagron BV, which is
headquartered in Rotterdam.
In the event of differences between the
English translation and the Dutch original of this press release,
the latter prevails.
- Fagron publishes annual report 2024
Fagron NV (EU:FAGR)
Historical Stock Chart
From Mar 2025 to Apr 2025
Fagron NV (EU:FAGR)
Historical Stock Chart
From Apr 2024 to Apr 2025
